Background:

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.

Clonality:

polyclonal

Classification:

Primary antibody

Alternative names:

CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27, P27; KIP1, P27KIP1

Specificity:

Human, Mouse, Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

cyclin-dependent kinase inhibitor 1B(p27, Kip1)

Purification:

Immunogen affinity purified

Purity:

≥95% as determined by SDS-PAGE

Calculated molecular weight:

21 kDa

Form:

liquid

Applications:

ELISA, WB, IP, IHC, IF

Recommended dilution:

WB: 1:200-1:2000; IP: 1:200-1:1000; IHC: 1:50-1:500; IF: 1:50-1:500

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com